Outcomes of patients with left ventricular ejection fraction preserved heart failure and iron deficiency treated with intravenous iron / 实用医学杂志
The Journal of Practical Medicine
; (24): 2148-2150, 2017.
Article
in Zh
| WPRIM
| ID: wpr-617018
Responsible library:
WPRO
ABSTRACT
Objective The aim of this study was to evaluate the benefits of i.v. iron therapy in iron-defi-cient patients with left ventricular ejection fraction preserved heart failure (HFpEF). Methods 61 HFpEF pa-tients with iron deficiency were randomized to treatment with or without i.v. iron,as ferric carboxymaltose(FCM, n = 31)or placebo(saline,n = 29)for 24 weeks of a double-blind,placebo-controlled trial. The primary end-point was the change in 6-min-walk-test(6MWT)distance from baseline to Week 24. Secondary end-points includ-ed changes in New York Heart Association(NYHA)class,health-related quality of life(QoL),with NT-proBNP under observation. Results Compared with the control group at week 16 and 24,the iron treatment group has much more improve in 6MWT and the health-related quality of life(HRQoL)(P0.05). Conclusion In this study,Treatment with intravenous ferric carboxymaltose can improve symptoms, functional capacity,and quality of life.
Full text:
1
Database:
WPRIM
Type of study:
Clinical_trials
Aspects:
Patient_preference
Language:
Zh
Journal:
The Journal of Practical Medicine
Year:
2017
Document type:
Article